Home / Intelligence / Blog / Verily to Acquire SignalPath, Expanding the Company’s Clinical Research Capabilities
Published August 30, 2021
Verily recently announced its first major acquisition, a software platform known as SignalPath. SignalPath’s flagship software, TrialPath, digitizes and modulates individual protocols in a clinical trial, from budgeting to tracking point-of-care communication. The acquisition would fold SignalPath into Baseline, Verily’s clinical research platform designed to improve clinical trial execution, help research manage their clinical trials, and explore flexible study options for decentralized and hybrids trials as well as novel ways to capture real-world data (i.e., generated by novel sensors and biomarkers).
While many details of the agreement were not disclosed, including the financial terms, this deal could “set a new standard for clinical studies and evidence generation,” according to Amy Abernethy, MD, PhD, a former principal deputy commissioner at the FDA and current President of Clinical Studies Platforms at Verily. With a tech giant backing and a growing pipeline of digital technologies, including a virtual clinic that provides online care and coaching for chronic conditions, Verily can now use a new system to accelerate its research and trial processes, to quickly establish its presence in the DTx.
Written by Crystal Zhao and Kate Watkins
Related Intelligence
White Papers
Predicting Winners: AI-Powered Portfolio Management
Can artificial intelligence and machine learning (AIML) be used to support portfolio decision-making across the life sciences industry? In this installment of our Industry Impact Series, we find that not only can the latest AIML techniques identify the drivers of success and failure in commercialization, but Trinity Life Sciences’ AI algorithm accurately predicts revenue outcomes for […]
Read More
Webinars
Health Equity in HTA Outcomes: Navigating the New Frontier
April 30, 2025 | 11:00 – 11:45 AM ET / 17:00 – 17:45 CET
Join Value, Access and Pricing experts as they delve into the emerging role of health equity considerations as a differentiator in value narratives for global HTA (Health Technology Assessment) submissions. NICE’s proposed methods update focused on manufacturer-submitted evidence on health inequalities.
Sign Up Now
Blog
The Evolution of CRM in Life Sciences: Navigating the Split
The split between Veeva and Salesforce marks a significant shift in the CRM landscape. Veeva is removing its CRM from the Salesforce cloud in September 2025 to focus on its “Veeva Vault” cloud solution for CRM. Veeva has communicated that it will maintain the current CRM product until September 2030 but will not be making any updates—and that it will absorb the cost of migration to the new Vault platform for all customers, excluding any customizations and integrations.
Read More